Pharma
-
Bristol Myers Squibb vs Vertex: Investment Merits Compared Ahead of 2027
Analysis of financial performance and sector trends pits steady value Bristol Myers Squibb against high-growth Vertex Pharmaceuticals for personal finance readers ahead…
-
How Amivantamab’s Dual EGFR-MET Blockade Overcomes Resistance in Head and Neck Cancer
The first new drug in a decade for advanced HNSCC uses a bispecific antibody to hit two escape pathways at once, doubling…
-
Zanidatamab’s Dual-Targeting Design Offers Alternative To Trastuzumab Deruxtecan
Zanidatamab’s unique mechanism and clinical data show promise for HER2-positive cancer treatment
-
FDA expands Anktiva approval to cover papillary-only bladder cancer, first treatment for this group
The FDA has broadened Anktiva’s use with BCG to include patients with BCG-unresponsive, high-grade papillary-only non-muscle-invasive bladder cancer, offering a bladder-preserving option…
-
Academic Pioneers to Pharma Giants Drive CAR-T Therapy
PHILADELPHIA, July 7, 2026 — Dr. Carl June, director of the Center for Cellular Immunotherapies at the University of Pennsylvania, is widely…
-
ALS Patient Improves, Still Works as Physician After RNA Therapy
BETHESDA, September 19 — A man with a rare, inherited form of amyotrophic lateral sclerosis has become the first person to receive…
-
PAHO Opens HIV Prevention Injection Access for Fourteen Nations
WASHINGTON, September 15 — The Pan American Health Organization announced a new pathway on Tuesday that will let 14 countries in Latin…
-
Fenfluramine: From Fen-Phen scandal to seizure drug
NEW YORK, July 22 — Fenfluramine is back on the American market, a comeback twenty-three years in the making. The same drug…
-
Ernexa Plans Fourth-Quarter First-in-Human Trial of ERNA-101 in Ovarian Cancer
SAN FRANCISCO, July 15 — Ernexa Therapeutics, a biotechnology company operating in the U.S. healthcare sector, is preparing to advance its lead…
-
Ernexa Moves ERNA-101 Into GMP Manufacturing Ahead of Planned IND Filing
KARACHI, July 15 — Ernexa Therapeutics is moving toward a planned first-in-human Phase 1 study for its lead cancer candidate, ERNA-101, though…
-
Ernexa Plans IND Filing in Q3 and Ovarian Cancer Trial in Q4 2026
NEW YORK, July 15 — Ernexa Therapeutics is moving its lead candidate ERNA-101 toward a first-in-human Phase 1 study, with the trial…
-
Ernexa Therapeutics Advances ERNA-101 to First-in-Human Trial Planning
SINGAPORE, July 15 — A new cancer therapy candidate is taking its first step from the laboratory bench toward the bedside, with…
-
Akeso starts US Phase II cadonilimab trial in gastric cancer with Memorial Sloan Kettering
ISLAMABAD, July 15 — Akeso, the Chinese biopharmaceutical company, has advanced its investigational drug cadonilimab into a Phase II clinical trial in…
-
Chinese Biotech Deals With Big Pharma Surge as Drugmakers Face Patent Cliff
BEIJING, July 13 — Cross-border deals for innovative drugs originating from China have reached a record US$110 billion in the first half…
-
CAR-T Sales in 2023: Gilead’s Yescarta Led at $1.5 Billion as Kymriah Slipped
ISLAMABAD, July 7 — The global market for CAR-T cell therapy, a personalized cancer treatment that reprograms a patient’s own immune cells…
-
Global Oncology Precision Medicine Market Set for Robust Expansion Through 2031
GLOBAL — July 1, 2026 — The global market for oncology precision medicine is opening up fresh opportunities in diagnostics and therapeutics,…
-
Ipsen completes Kartos acquisition and adds navtemadlin to its myelofibrosis pipeline
The clinical trial is called POIESIS. More than 600 patients. Over 250 sites worldwide. It is testing navtemadlin as an add-on to…
-
Takeda’s Oveporexton Meets All Endpoints in Two Phase 3 Narcolepsy Type 1 Trials
In July 2025, Takeda announced that its experimental wake‑promoting drug, oveporexton, successfully completed phase 3 clinical testing for narcolepsy. The trial results…
-
FDA Approves New Schizophrenia Medication With Unique Mechanism
The U.S. Food and Drug Administration granted approval on September 15, 2024, for a new fixed-dose combination medication designed to treat schizophrenia.…
-
FDA Approves Lazertinib With Amivantamab as First-Line Treatment for EGFR Lung Cancer
For patients with a common form of lung cancer, a new treatment option arrived in the United States on August 15, 2024.…
-
FDA Approves Yuhan’s Lazertinib, First Korean-Developed Cancer Drug to Win Approval
South Korea, August 16, 2024 — cyberinktimes.com — Almost four years after South Korean regulators gave it the green light, Lazertinib has…
-
Lazertinib Approved in US for Non-Small Cell Lung Cancer Treatment
In August 2024, the U.S. Food and Drug Administration granted approval for lazertinib, expanding the therapeutic arsenal against non‑small cell lung cancer…
-
FDA Approves Imetelstat for Treating Myelodysplastic Syndromes with Anemia
In a pivotal shift for the cancer treatment landscape, the US Food and Drug Administration (FDA) granted approval on June 15, 2024,…
-
CGRP Drugs and a Wearable Device Give Migraine Patients New Treatment Options
Migraine attacks often strike without warning, bringing intense pain, light sensitivity and nausea. Traditional acute treatments have been limited, and preventive regimens…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
New Studies Show Immunotherapy Gaining Ground in Lung, Prostate and Childhood Cancers
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Why Broad RAS-Targeting Drugs Mark a Turning Point in Treating Pancreatic Cancer
-
How At-Home Igalmi Differs From Traditional Treatments for Schizophrenia and Bipolar Agitation
-
Boron Neutron Capture Therapy Faces US Coverage Hurdles Over Cost and Data Gaps
-
FDA Proposes Slashing Companion Diagnostic Fees From $636,732 to $28,653
-
Biocon’s Pebrilzo FDA Approval Cements Its Role in Affordable Cancer Care
-
Navigating 7% Mortgage Rates: Strategies for Buying a Home Now
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992
























